HUM — Humana Inc.

The tape is constructive after Q2 2026 adjusted EPS of $7.61, strong MA membership growth, and recent price-target hikes from Wolfe and Piper Sandler, but the Street's consensus is still Hold (16 buy / 27 hold / 1 sell, average target $418.53). Investors are waiting for proof that margin recovery, Stars recovery, and 2027 bid discipline actually flow through to reported profitability.

Revenue is inflecting upward, not just growing: YoY growth accelerated from ~8-9% in 2024 to 11% in 2025 and ~23.5%/26.2% in Q1/Q2 2026, helped by MA membership up ~23.8% YoY and acquisitions. Profitability is far lumpier - Q4 losses of -$4.42, -$5.76 and -$6.61 EPS in 2023-2025 are a recurring seasonal pattern, not proof of structural collapse, but they keep TTM operating margin at only ~1.4% and TTM EPS at $10.63. H1 2026 operating margin of ~3.65% is essentially stable versus H1 2025, so the story is revenue acceleration with margins bottoming, not yet expanding.

At $392.63, trailing P/E is 36.9 versus the 5-year average of 23.5, but that trailing multiple is distorted by seasonal Q4 losses and one-off items. On a normalized adjusted EPS base around $16, the forward P/E is roughly 24.5x, almost exactly in line with the 23.5x 5-year average. P/S of 0.32 is below the 5-year average of 0.49, and P/B is 2.46. Net assessment: fair, not cheap; the stock is not pricing in a bargain, but it is also not pricing in a flawless recovery.

The market is paying up for a 2027-2028 earnings recovery before it appears in GAAP numbers. With TTM EPS of $10.63 and FMP's next-FY EPS estimate of $9.15 (a GAAP, seasonally depressed number), the stock looks expensive; with adjusted EPS power of ~$16 and a plausible path to 3% Medicare Advantage pre-tax margins by 2028, $392.63 is roughly fair. The playbook is to own it for the margin/Stars recovery rather than for current reported earnings, which makes October and December 2026 data releases the key validation points.

As of 2026-08-27, RSI is 57.1 (neutral, not overbought), price is 3.3% above the 20-day and 2.1% above the 50-day, and 42.8% above the 200-day. That is a solid uptrend, but the distance from the 200-day suggests a consolidation/pullback is normal. Momentum favors owning dips toward the 20/50-day area rather than chasing strength.

• CMS Medicare Advantage rate-setting and reimbursement pressure remain the dominant sectorwide swing factor.
• CMS Stars quality ratings determine bonus revenue; October 2026 releases are a major catalyst for Humana specifically.
• Medical cost/utilization trends are running in the guided high-single-digit range; any upside in inpatient or specialty costs hits MLR directly.
• Regulatory and legal overhangs in managed care - antitrust, drug pricing, Medicaid redeterminations - create headline risk.
• Balance-sheet/rates: D/E is 0.74 and the company added a $1.5B contingent capital facility plus a ~$900M Gentiva divestiture, so liquidity and leverage are manageable if rates stay elevated.

• October 2026: CMS Stars ratings, Q3 earnings, and MA plan-finder data will show whether 2027 benefit design and margin-over-growth strategy is working.
• December 10, 2026 Investor Update: management is expected to lay out the detailed path to 2028 Stars recovery and 3%+ pre-tax margins.
• Close of Gentiva minority-interest sale (~$900M) in Q4 2026, which largely funds prior CenterWell/MaxHealth acquisitions.
• DaVita value-based kidney-care partnership and Medicaid expansion under new leadership could add high-quality membership beyond core MA.

• Medical cost trend re-accelerates above 7-8% guidance, compressing margins in a low-margin business.
• CMS Stars ratings fail to improve, leaving bonus revenue and 2028 margin targets out of reach.
• Planned exits of ~600k MA members in 2027 hurt revenue growth and market position before margin benefits arrive.
• Regulatory/legal actions, further MA rate cuts, or another Q4-style reserve/charge shock undermines the adjusted-earnings narrative.

Humana is a credible margin-recovery story at a fair price, not a clear bargain. The revenue acceleration and management's Stars/margin focus give a real path to higher earnings, but reported profitability is still depressed and the heavy lifting (Stars, 2027 bids, medical cost control) is ahead. I would be a buyer closer to the low-$300s or after the December 2026 investor update confirms the 2028 margin bridge.

I applied a 25x multiple to normalized adjusted EPS of roughly $16.00 (derived from Q2 adjusted EPS of $7.61, a strong Q1 GAAP EPS of $9.83, and management's reaffirmed full-year adjusted guidance). The 25x multiple is a small premium to Humana's 23.5x 5-year average P/E, reflecting accelerating revenue growth and margin-recovery optionality while leaving some room for Stars/regulatory execution risk.